Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk.
Interference of antiphospholipid antibodies (aPL) with coagulation was investigated in 40 aPL-patients (24 with thrombosis) using thrombography. Impairment of the activated protein C anticoagulant pathway was partially offset by the genuine anticoagulant effect. The net result, a procoagulant phenotype, was associated with a 7-fold increased risk of thrombosis in aPL-patients.
Lecompte
Thomas
T
Wahl
Denis
D
Perret-Guillaume
Christine
C
Hemker
H Coenraad
HC
Lacolley
Patrick
P
Regnault
Véronique
V
D020016:Activated Protein C Resistance / Q000097:blood / Q000276:immunology; D000328:Adult; D000368:Aged; D017152:Antibodies, Antiphospholipid / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000097:blood* / Q000150:complications / Q000276:immunology; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D016682:Lupus Coagulation Inhibitor / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012306:Risk; D019851:Thrombophilia / Q000097:blood* / Q000209:etiology / Q000276:immunology; D013927:Thrombosis / Q000453:epidemiology*
D017152:Antibodies, Antiphospholipid; D016682:Lupus Coagulation Inhibitor